News about Transcode Therapeutics Inc

Harnessing microRNA TransCodes Pioneering Path Against Metastatic Cancer,
Oct 10 2024
Unlocking the Secrets of MicroRNA: TransCode Therapeutics Journey Toward Combatting Metastatic Cancer In the ever-evolving world of biotech innovatio...

Pioneering Advances in RNA Therapeutics TransCode Therapeutics Initiates Phase 1 Clinical Trial for Novel Lead Cand...
Sep 17 2024
: TransCode Therapeutics has announced the successful initiation of its Phase 1 clinical trial, marking a significant milestone in the field of RNA-b...

Disrupting Metastasis TransCode Therapeutics TTX-MC138 Paves a New Path in Cancer Treatment with Unpreced...
Sep 10 2024
TransCode Therapeutics, an innovative biotech company, has recently announced the publication of several pivotal studies revealing the profound potent...

Navigating Challenges and Opportunities TransCode Therapeutics Secures $2 Million NIH Grant Amid Financia...
Sep 05 2024
TransCode Therapeutics Inc., a clinical-stage biopharmaceutical company focusing on developing RNA-targeted therapeutics for cancer treatment, has rec...

TransCode Therapeutics Secures Funding for RNA Oncology Treatments: Impact on Shareholders and Financials
Jul 24 2024
TransCode Therapeutics Continues to Secure Funding for Innovative RNA Oncology Treatments: Impact on Shareholders and FinancialsIn recent news, T...

TransCode Therapeutics, Inc. Shows Growth in Cash and Quick Ratio in Q3 2024
Jul 23 2024
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has recently released its financial report for the third quarter of 2024, showcasing positive de...

TransCode Therapeutics, Inc. Raises $8.5 Million in Public Offering to Drive Breakthroughs in RNA Oncology Research
Jul 22 2024
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage RNA oncology company, has recently announced the successful closure of its public offeri...

Transcode Therapeutics Inc Aiming for Success in a Volatile Market
Jun 25 2024
In the ever-evolving world of pharmaceuticals, Transcode Therapeutics Inc (RNAZ) has emerged as a player to watch. Despite facing challenges and marke...

TransCode Therapeutics TTX-MC138 Demonstrates Promising Potential in First-in-Human Cl...
May 29 2024
The field of oncology has seen remarkable advancements in recent years, particularly with the emergence of RNA therapeutics. Among the notable contrib...

Transcode Therapeutics Inc Reports Operating Deficit of $-4.059033 Million in Q4 20232.
Apr 03 2024
According to the recent earnings reports, TransCode Therapeutics Inc (NASDAQ: RNAZ), a major player in the Major Pharmaceutical Preparations sector, d...

Revolutionizing Cancer Therapeutics: TransCode Therapeutics and Debiopharm Unite to Pave the Way for Targeted Nucleic Acid Therapies
Jan 29 2024
...

Transcode Therapeutics Inc*s Fiscal Period Sees Decline in Company Results2.
Nov 16 2023
Transcode Therapeutics Inc: An Optimistic Outlook for the FutureAs the earning season for the Major Pharmaceutical Preparations industry unfolds,...